Sources and Prices of Selected Medicines and Diagnostics for People Living with HIV/AIDS: Annex 6. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries: Tables: Table 2: Company ARV offers and restrictions for developing countries, adult and paediatric formulations: Table 2b - Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Sources and Prices of Selected Medicines and Diagnostics for People Living with HIV/AIDS
(2003; 92 pages) [French] [Spanish]

Table of Contents

Glossary
1. Introduction
2. Pricing
3. Access to quality HIV/AIDS medicines and diagnostics
4. Sources & prices of medicines
5. Variation in price between surveys
Annex 1A. Registration status of products included in the sources and prices survey
Annex 1B. Index of manufacturers
Annex 1C. Geographical distribution of par ticipating manufacturers
Annex 2. WHO Bulk Procurement Scheme 2003
Annex 3A. Summary of main characteristics of methods forCD4/CD8 lymphocyte determination
Annex 3B. Summary of main characteristics of viral load technologies
Annex 4. Further reading, references, and contacts
Annex 5. Feedback and enquiry form
Annex 6. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries
	General background and objectives
	Methodology
	Limitations of the current system
	The challenge of paediatric formulations
	Research and development for HIV/AIDS
	The Effects of Generic Competition
	Guide to reading and using tables
	Tables
		Table 1: Summary of selected pharmaceutical companies’ best ARV price offers for eligible developing countries
			Table 1a - Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
			Table 1b - Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
			Table 1c - Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)
			Table 1d - Protease Inhibitors (PIs)
			Table 1e - Fixed Dose Combinations (FDCs)
			Table 1f - Paediatric Formulations
		Table 2: Company ARV offers and restrictions for developing countries, adult and paediatric formulations
			Table 2a - Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
			Table 2b - Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
			Table 2d - Protease Inhibitors (PIs)
			Table 2e - Fixed Dose Combinations
			Table 2f - Selected generic companies’ ARV offers and restrictions for developing countries
	Annexes
		Annex 1: Least Developed Countries (LDCs)
		Annex 2: Human Development Index (HDI)
		Annex 3: Sub-Saharan countries
		Annex 4: World Bank low-income countries
		Annex 5: Company contacts
		Glossary¹²
		References

Table 2b - Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Product	Company	Eligibility (countries)	Eligibility (body)	Price in US$	Additional comments	Delivery of goods[5]
efavirenz (Stocrin®)	Merck & Co., Inc.	Low Human Development Index (HDI) countries plus medium HDI countries with adult HIV prevalence of 1% or greater¹⁰ .	Governments, international organisations, NGOs, private sector organisations (e.g. employers, hospitals and insurers). Merck & Co., Inc. does not rule out supplying ARVs to patients through retail pharmacies.	600 mg tablet: US$ 346.75/year (US$ 0.950/unit) 200 mg capsule: US$ 500/year (US$ 0.457/unit) 50 mg capsule: US$ 0.116/unit US$ 3.47 per bottle of 30	Although Romania does not fall under these categories it also benefits from these prices due to a government commitment to a programme of universal access.	CIF
efavirenz (Stocrin®)	Merck & Co., Inc.	Medium HDI countries with adult HIV prevalence less than 1%¹⁰.	Governments, international organisations, NGOs, private sector organisations (e.g. employers, hospitals and insurers). Merck & Co., Inc. does not rule out supplying ARVs to patients through retail pharmacies.	600 mg tablet: US$ 767/year (US$ 2.10/unit) 200 mg capsule: US$ 920/year (US$ 0.840/unit) 50 mg capsule US$ 0.213 per unit US$ 6.39 per bottle of 30		CIF
nevirapine 200 mg tablets (Viramune®)	Boehringer Ingelheim	All World Bank low-income countries and sub-Saharan Africa. (Other countries on a case-by-case basis.)	Governments, NGOs and other partners who can guarantee that the programme is run in a responsible manner.	US$ 438/year (US$ 0.600/unit)		CIF
nevirapine 10 mg/ml suspension 240 ml (Viramune®)	Boehringer Ingelheim	All World Bank low-income countries and sub-Saharan Africa. (Other countries on a case-by-case basis.)	Governments, NGOs and other partners who can guarantee that the programme is run in a responsible manner.	US$ 17.50 per unit		CIF
tenofovir 300 mg (Viread®)	Gilead	53 nations in Africa and 15 other UN-designated ‘least developed’ countries.	Organisations that provide HIV treatment in the 68 countries covered by the Viread Access programme will be able to receive Viread at the access price. Applications will go through a review process.	US$ 475/year (US$ 1.30/unit)	The programmes will be managed through Axios.	FOB